Orexo CEO on EU approval: Great need and potential for Zubsolv

The Swedish drug group Orexo, in which Novo Holdings holds parts of the shares, has obtained an approval of its main asset in EU. Zubsolv treats addiction to pain-relieving medicine and according to the company’s Danish CEO, mint taste, multidoses, and shorter resolving time make the drug a potential winner.

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us free for 14 days

Try a trial subscription for free access to our quality journalism

Frontpage right now

MSD's Keytruda fejler i mavekræftstudie

Immunterapien Keytruda fra amerikanske Merck/MSD har ikke kunnet overgå kemoterapi i andenlinjebehandling af patienter med kræft i mave eller spiserør. Lægemidlet blev for få måneder siden godkendt i indikationen i tredje linje.

Latest Top picks in English

Related articles